Unfortunately, tumor tissue available did not allow for the inclusion of p-AKT as an additional parameter of interest to assess the compensatory feedback loop through the mTORC2-AKT pathway, following mTORC1 inhibition with everolimus [8]. This evidence concerns the gene AKT1 and neoplasm.